Medicamen Biotech Ltd-has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 12/08/2025 ,inter alia, to consider and approve unaudited (Standalone and ....
MEDICAMEQ · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Medicamen Biotech has informed BSE that its Board of Directors will meet on Tuesday, August 12, 2025, at the registered office in New Delhi. Key agenda items include approval of unaudited standalone and consolidated financial results for Q1 FY26 (quarter ended June 30, 2025), the draft Annual Report for FY 2024-25, and the draft Cost Audit Report for FY 2024-25. The Board will also consider appointing Mr. Ashwani Kumar Sharma as Whole-time Director (Executive Director) for five years, and Mr. Sham Goel and Mr. Shaival Saurabh as Non-Executive Independent Directors, all subject to shareholder approval. The trading window for designated persons is already closed since July 1, 2025 and will reopen 48 hours after the financial results are declared.
This is a routine pre-results intimation. Shareholders should watch for the Q1 FY26 numbers and director appointments on/after August 12, which could influence short-term stock movement and governance perception.